Squarepoint
PHAT icon

Squarepoint’s Phathom Pharmaceuticals PHAT Stock Holding History

Squarepoint’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.06M Buy
+275,161
New +$3.48M ﹤0.01% 1878
2023
Q4 		– Sell
-18,815
Closed -$195K – 4375
2023
Q3 		$195K Buy
+18,815
New +$258K ﹤0.01% 3417
2023
Q1 		– Sell
-12,296
Closed -$138K – 3667
2022
Q4 		$138K Sell
12,296
-22,110
-64% -$228K ﹤0.01% 2896
2022
Q3 		$381K Buy
34,406
+18,529
+117% +$177K ﹤0.01% 2343
2022
Q2 		$134K Buy
+15,877
New +$163K ﹤0.01% 2579
2021
Q2 		– Sell
-11,186
Closed -$420K – 3588
2021
Q1 		$420K Sell
11,186
-17,387
-61% -$727K ﹤0.01% 2150
2020
Q4 		$949K Buy
+28,573
New +$1.16M 0.01% 1371

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return